The Hidden Cost of Gout Save

For many people, gout is viewed as an episodic disease: a painful flare, a short course of treatment, and then life returns to normal. However, as rheumatologists, we know that recurrent attacks can lead to joint damage and tophi if left untreated. Furthermore, the true burden of gout extends far beyond the musculoskeletal system (1). Increasing evidence suggests that gout is associated with poorer quality of life, greater psychological burden, more frequent serious infections, and even reduced survival (2, 3). These are the hidden costs of a disease that is too often dismissed as “just gout.”

Perhaps the most striking observation is the association between gout and mortality. 

Large population-based studies consistently show that patients with gout have a significantly higher risk of all-cause mortality than the general population, with cardiovascular disease the leading cause of death (4). Importantly, this excess risk persists even after accounting for many traditional cardiovascular risk factors (5). While hyperuricaemia itself may not be directly causal, a diagnosis of gout should prompt clinicians to recognise that these patients represent a high-risk population who deserve aggressive cardiovascular risk assessment and optimisation alongside urate-lowering therapy.

Quality of life is another outcome that is frequently underestimated (2). Patients with recurrent gout often describe living with uncertainty, never knowing when the next flare will occur. Repeated attacks affect mobility, employment, sleep and independence, while chronic tophaceous disease can cause visible deformity and functional disability (6). Studies consistently demonstrate poorer health-related quality of life in patients with gout compared to the general population, particularly among those with frequent flares or uncontrolled disease. These impacts are rarely reflected by serum urate measurements alone.

The psychological consequences are equally important (7). Depression and anxiety occur more frequently in patients with gout than in matched controls, yet they often receive little attention during routine consultations (8). Pain, disability, recurrent healthcare encounters and the persistent misconception that gout is entirely lifestyle-induced can all contribute to feelings of guilt and stigma. These psychological effects may, in turn, reduce treatment adherence and engagement with long-term urate-lowering therapy, perpetuating a cycle of recurrent disease.

Infection is another overlooked consequence of gout (9). Acute gout frequently presents as a hot, swollen joint indistinguishable from septic arthritis, and the two conditions can coexist (10). Finding monosodium urate crystals should therefore never end the diagnostic evaluation when infection remains a possibility. Beyond septic arthritis, patients with gout are at increased risk of serious infections and infection-related hospitalisation. This likely reflects the combination of older age, as well as common comorbidities in this population such as chronic kidney disease, diabetes and repeated exposure to corticosteroids during recurrent flares.

Perhaps the biggest misconception about gout is that it is simply a disease of uric acid crystals. Increasingly, the evidence tells a different story. Patients with gout are more likely to be hospitalised, develop serious infections, experience impaired quality of life and die prematurely than those without gout. These outcomes are driven by a complex interplay of inflammation, multimorbidity and the cumulative burden of recurrent disease. Looking beyond the acute flare helps us appreciate that gout is often a marker of patients with substantial long-term health risks.

For rheumatologists, this presents an opportunity. Every gout consultation should extend beyond treating the current flare and achieving a target serum urate. It is a chance to review cardiovascular and renal health, minimise glucocorticoid exposure, optimise long-term urate-lowering therapy, and address the physical and psychological consequences of recurrent disease. We cannot modify every risk factor, but we can recognise gout as a prompt to signpost to relevant and necessary multidisciplinary care. That may ultimately be the best way to reduce the hidden cost of gout.

References

1. Cross M, Ong KL, Culbreth GT, Steinmetz JD, Cousin E, Lenox H, et al. Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology. 2024;6(8):e507-e17.

2. Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology. 2013;52(11):2031-40.

3. Han Y, Cao Y, Han X, Di H, Yin Y, Wu J, et al. Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey. Journal of Translational Medicine. 2023;21(1).

4. Wang X, Li X, Wang H, Chen M, Wen C, Huang L, et al. All-cause and specific mortality in patients with gout: A systematic review and meta-analysis. Semin Arthritis Rheum. 2023;63:152273.

5. Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(3):335-43.

6. Diaz-Torne C, Pou MA, Horne A, Gasteiger C, Dalbeth N. 'Gout was like the boss'. A qualitative study exploring the impact of gout on employment. RMD Open. 2024;10(3).

7. Douglas M, Yielder R, Kleinstäuber M, Borgmann A, Karu LT, Dalbeth N, et al. The Big Picture: Patient Drawings of Gout and Their Relationship to Illness Perceptions and Stigma. The Journal of Rheumatology. 2024;51(2):203-5.

8. Howren A, Bowie D, Choi HK, Rai SK, De Vera MA. Epidemiology of Depression and Anxiety in Gout: A Systematic Review and Metaanalysis. The Journal of Rheumatology. 2021;48(1):129-37.

9. Singh JA, Cleveland JD. Serious Infections in Patients With Gout in the US: A National Study of Incidence, Time Trends, and Outcomes. Arthritis Care & Research. 2021;73(6):898-908.

10. Dey M, Al-Attar M, Peruffo L, Wilson I, Duffield SJ, Zhao SS, et al. A systematic review of the assessment and diagnosis of the acute hot joint.